Stability indicating simultaneous validation of hydrochlorothiazide, dihydralazine, and propranolol with thestudy of forced degradation behavior through RP-HPLC in thepharmaceutical dosage form by Akhilesh Sharma et al.
 
Asian Pac. J. Health Sci., 2017; 4(3):292-305                                          e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________  
Sharma et al                               ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2017; 4(3):292-305 
www.apjhs.com                                    292 
 
 
Document heading        doi: 10.21276/apjhs.2017.4.3.44                                                                                      Research Article 
 
Stability indicating simultaneous validation of hydrochlorothiazide, dihydralazine, and 
propranolol with thestudy of forced degradation behavior through RP-HPLC in 
thepharmaceutical dosage form 
 
Akhilesh Sharma1, Anurag Mishra1, Sanjay Sharma2 
 
1Faculty of Pharmaceutical Sciences, Pacific Academy of Higher Education and Research University, Udaipur 
(Rajasthan), India 
2School of Pharmacy and Technology Management, SVKM’S, NarseeMonjee Institute of Management Studies, 
Mumbai-Agra Road, Shirpur-425405, India 
 
Received: 15-06-2017 / Revised: 02-07-2017 / Accepted: 20-09-2017 
 
ABSTRACT 
 
For the instantaneous assay of Hydrochlorothiazide, Dihydralazine and Propranolol in tablet, an easy, accurate and 
truthful RP-HPLC method have been developed as well as validated. Isocratic RP-HPLC method was developed on 
BDS hypersil C18, (250mm×4.6mm internal diameter, 5µ particle size) using mobile phase as 0.05M Potassium 
Dihydrogenortho Phosphate (pH-6.0): Acetonitrile (40:60v/v) at a 1.0 mL/min flow rate than at 215 nm detection 
was carried out using tunable absorbance detector (Waters 486). Study of forced degradation study was carried out 
through acid degradation, base degradation, thermal degradation, oxidation of the drug. The validation of method 
was carried out to observe accuracy, precision, linearity, in addition to robustness. The method was found to be 
linear in the concentration range of 10-30𝜇g/mL with correlation coefficient of 0.9996 for 
Hydrochlorothiazide,12.5-37.5𝜇g/mL with correlation coefficient of 0.9986 for Dihydralazine, and 20-60𝜇g/mLwith 
correlation coefficient of 0.9997 for Propranolol. Stress studies produce degradation products which did not hinder 
with the detection of Hydrochlorothiazide, Dihydralazine and Propranolol; therefore, the assay can be stability 
indicating. 
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Introduction 
Hydrochlorothiazide’s empirical formula is 
C7H8CLN3O4S2and its IUPAC name is 6-chloro-1,1-
dioxo-3,4-dihydro-2H-1λ⁶,2,4-benzothiadiazine-7-
sulfonamide. Figure 1demonstrates Hydro chloro 
thiazide chemical structure. Hydrochlorothiazide is a 
thiazide class of diuretic frequently considered the 
ideal associate of this class. It decreases the electrolytes 
reabsorption from the renal tubules in the kidney. This 
lead to increased electrolytes such as potassium, 
chloride, sodium, as well as magnesium.  
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It has been used in the numerousillnesses treatment like 
hypertension, diabetes, hypoparathyroidism, and 
edema. Dihydralazine’s empirical formula is C8H10N6 
and its IUPAC name is 4-Hydrazinyl-1-
hydrazinylidene-1,2-dihydrophthalazine. Figure 2 
shows chemical structure of Dihydralazine. 
Dihydralazine is a drug-related to the treatment of 
hypertension. 
It relates to the class of hydrazinophthalazine and 
almost same effects to hydralazine. Dihydralazine is a 
vasodilator with direct action which acts principally on 
the arterioles. It decreases blood pressure and 
peripheral resistance, therefore, increasing cardiac 
output. It also has a tendency toprogresscerebral and 
renal flow of blood and its effect on diastolic pressure 
is additionally noticeable compared to systolic 
pressure. Propranolol’s empirical formula is 
C16H21NO2and its IUPAC name is 1-
(naphthalen1yloxy)-3-[(propane-2-yr)amino]propan-2-
ol.Figure 3 shows the chemical structure of 
Propranolol. Propranolol is a non-selective β-
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adrenergic antagonist with no intrinsic 
sympathomimetic activity. It is used in the 
hypertension management, phaeochromocytoma, 
thyrotoxicosis, angina pectoris, myocardial infarction, 
and cardiac arrhythmias. 
Literature survey reveals that quantitative analysis of 
Hydrochlorothiazide, Dihydralazine, and Propranolol 
have been done separately or in acombination of two 
and in acombination of other drugs but no any method 
is stated for the simultaneous valuation of 
Hydrochlorothiazide, Dihydralazine and Propranolol in 
the combined type of dosage form. The present study 
involved the development and validation of anRP-
HPLC method for the estimation of 
Hydrochlorothiazide, Dihydralazine and Propranolol in 
combined pharmaceutical dosage form (tablet) and 
their forced degradation study[1-5]. 
Material and Methods 
Instruments 
The liquid chromatographic system consists of Waters 
series M510 equipped with a tunable absorbance 
detector (Waters 486), HPLC pump (Waters 510), and 
manual injector rheodyne valve with 20 𝜇L fixed loop. 
The analytes were observed at 215 nm. 
Chromatographic analysis was performed on Thermo 
scientific BDS hypersil C18, (250mm × 4.6mm internal 
diameter, 5µ particle size). By using the citizen 
electronic balance all the chemicals and drugs were 
weighed. Chemiline India pH meter and Toshcon 
Ultrasonicator was used. 
Chemicals and reagents 
Acetonitrile was of HPLC grade obtained from Merck 
Ltd., Mumbai. Water was of HPLC grade prepared by 
triple distillation method. Potassium Dihydrogen 
Phosphate, Sodium Hydroxide (NaOH), Hydrogen 
Peroxide (H2O2) and Hydrochloric Acid (HCl) were of 
AR grade and were obtained from Merck, Mumbai 
India. Hydrochlorothiazide reference standard was 
procured from Oasis Laboratories. Dihydralazine and 
Propranolol reference standards were procured from 
Gitar Laboratories. Beptazine H tablets containing 
20mg of Hydrochlorothiazide, 25mg of Dihydralazine 
and 40mg of Propranolol manufactured by MM labs 
were procured from local market. 
 
HPLC Conditions 
The mobile phase consisted of 0.05M Potassium 
Dihydrogen Ortho Phosphate (pH-6.0): Acetonitrile 
(40:60v/v).The mobile phase was freshly prepared, and 
it was sonicated by using Toshcon Ultrasonicator for 5 
min before use. BDS hypersil C18, (250mm×4.6mm 
internal diameter, 5µ particle size) was used and it was 
equilibrated for at least half an hour with the mobile 
phase flowing through the system. The HPLC system 
and column were kept at ambient temperature. The 
eluent was monitored by UV detection at 215 nm. The 
analysis was done at aflowrate of 1.0ml/min with 
the20μl volume of injection. All data were analyzed by 
using Empower 3 software. 
Preparation of Mobile Phase  
The mobile phase was prepared by mixing 0.05M 
Potassium Dihydrogen Ortho Phosphate (pH-6.0) and 
Acetonitrile in the ratio of (40:60%v/v). The solution 
was then filtered through 0.45 microns membrane filter 
and degassed. 
Preparation of 0.05M Potassium DihydrogenOrtho 
Phosphate (pH-6.0) 
Take about 6.8gm Potassium dihydrogen 
orthophosphate into a 1000ml beaker. Add 800ml 
water and dissolve. Adjust ph6.0 of this solution with 
0.1N Sodium hydroxide. Make up volume upto 1000ml 
with water. 
Preparation of standard stock solution 
A standard stock solution of Hydrochlorothiazide, 
Dihydralazine, and Propranolol were prepared by 
accurately weighing 20mg, 25mg, and 40mg 
respectively and dissolving them separately in 100ml 
with methanol to prepare asolution of 200𝜇g/mL, 
250𝜇g/mL and 400𝜇g/mL. 
Preparation of working standard solution 
Add 1ml each of standard stock solution of 
Hydrochlorothiazide, Dihydralazine,and Propranolol in 
10 ml volumetric flask and volume make up to 10ml 
with methanol. 
Preparation of sample stock solution 
Weigh tablet powder equivalent to 20mg of 
Hydrochlorothiazide, 25mg of Dihydralazine and 40mg 
of Propranolol) into a 100ml volumetric flask. Add 
60ml methanol andshake for 15 minutes. 
Makeupvolume with methanol upto 100ml. Filter this 
solution.  
Preparation of sample working solution 
Take 1ml from sample stock solution into a 10ml 
volumetric flask and makeup with mobile phase to 
prepare a solution of Hydrochlorothiazide 20mcg/ml, 
Dihydralazine 25mcg/ml and Propranolol 40mcg/ml. 
Forced Degradation Study 
Preparation of solution for acid degradation  
The study of acid decomposition was achieved by 
keeping the working solution of all three drugs (1 ml) 
in 2 ml of 0.1N HCl for 4 hrs. After 4hrs solution 
neutralized with 2ml 0.1N NaOH and lastly made up to 
thevolume of 10 ml with mobile phase, sonicated and 
filtered by 0.45μm membrane filter paper then 
insertedinto HPLC system. Degradation samples were 
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prepared as ablank sample, separate standard samples 
and acombined sample of all three drugs. 
 
 
Preparation of solution for basic degradation  
The study of alkali decomposition was performed by 
keeping the working solution of all three drugs (1 ml) 
in 2 ml of 0.1N NaOH for 3.5 hrs. After 3.5 hrs 
solution neutralized with 2 ml of 0.1N HCl and finally 
made up to 10 ml volume with mobile phase, sonicated 
and filtered through 0.45μm membrane filter paper and 
injected into HPLC system. Degradation samples were 
prepared as ablank sample, separate standard samples 
and acombined sample of all three drugs. 
Preparation of solution for oxidative degradation   
The study of oxidative decomposition was performed 
by keeping the working solution of all three drugs (1 
ml) in 2 ml 3% H2O2 for 4 hrs. After 4hrs volume made 
up to 10 ml with mobile phase, sonicated and filtered 
through 0.45μm membrane filter paper and injected 
into HPLC system. Degradation samples were prepared 
as ablank sample, separate standard samples and 
acombined sample of all three drugs. 
Preparation of solution for thermal degradation  
The study of thermal decomposition study was 
performed by refluxing the working solution of all 
three drugs (1 ml) for 3hrs at 105 ºC. After 3hrs 
volume made up to 10 ml volume with mobile phase, 
sonicated and filtered through 0.45μm membrane filter 
paper and injected into HPLC system. Degradation 
samples were prepared as ablank sample, separate 
standard samples and acombined sample of all three 
drugs. 
Preparation of solution for UV degradation  
The study of UV degradation was performed by 
exposing the working solution of all three drugs (1ml) 
to Sunlight for 3 hours. After 3 hours volume made up 
to 10 ml volume with mobile phase, sonicated and 
filtered through 0.45μm membrane filter paper and 
injected into HPLC system. Degradation samples were 
prepared as ablank sample, separate standard samples 
and acombined sample of all three drugs were 
prepared. 
Determination of λ max 
The UV spectra of standard stock solutions of 
Hydrochlorothiazide, Dihydralazine,and Propranolol 
were taken between the wavelength range of 200-
400nm using methanol as blank. The λ max was found 
to be 233.73nm, 250.66nm, and 207.02nm for 
Hydrochlorothiazide, Dihydralazine,and Propranolol 
respectively. Overlay of the three spectra taken and 
theiso-absorptive point was selected and it was found 
that all three drugs show appreciable absorbance at 215 
nm, so it is used for the further study. 
Procedure of Analysis 
1ml from Hydrochlorothiazide Standard stock solution, 
1ml from Dihydralazine Standard stock solution and 
1ml from Propranolol Standard stock solution were 
taken and volume was makeup to 10ml with Mobile 
phase to obtain aWorking standard solution containing 
Hydrochlorothiazide (20𝜇g/mL), Dihydralazine 
(25𝜇g/mL) and Propranolol (40𝜇g/mL).  
The contents of standard and sample solution were then 
filtered through 0.45 µm syringe filter. Chromatograms 
standard solution (six replicates) was recorded. A 
typical chromatogram of Hydrochlorothiazide, 
Dihydralazine,and Propranololis presented in figure 5. 
The retention time of Hydrochlorothiazide, 
Dihydralazine and Propranololwere 3.227 min, 9.097 
min,and5.807 min respectively. The peak areas were 
measured, and the quantitation was carried out by 
keeping these values to the regression equation of 
calibration curve. 
Optimized Chromatographic Condition: 
Stationary phase: Thermo scientific BDS hypersil C18 
(250mm × 4.6mm, 5µ). 
Mobile phase: Potassium dihydrogen orthophosphate 
(pH 6.0):Acetonitrile (40:60) 
Flow rate : 1.0 ml/min 
Run time (min) : 11min 
Detection: At 215 nm 
Injection (volume): 20μl 
 
Method validation procedure 
The developed method was validated for the 
parameters listed in ICH guidelines [6-13] 
Linearity  
The method was linear in the range of 10-30𝜇g/mL, 
12.5-37.5 𝜇g/mL and 20-60𝜇g/mL for 
Hydrochlorothiazide, Dihydralazine and Propranolol 
respectively. The linear correlation coefficient for 
Hydrochlorothiazide, Dihydralazine and Propranolol 
were found to be 0.9996, 0.9986 and 0.9997 
respectively, and are recorded in table 2, 3 and 4. 
Calibration curve of Hydrochlorothiazide, 
Dihydralazine and Propranolol was obtained by 
plotting the peak area ratio versus the respective 
concentrations (Figure 6, 7 and 8).  
Accuracy  
The accuracy of the developed method was evaluated 
by recovery experiments. Working standard with a 
known concentration was added to the fixed 
concentration of the pre-analyzed Drop solution. 
Calculation of percentage recovery was done by 
comparing the area before and after the addition of 
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working standard. In the same way, all the3 drugs 
recovery was performed. The studies of recovery were 
achieved in triplicate and outcomes are noted in table 
5.This standard addition method was performed at the 
level of 80%, 100%, 120% and the calculation of 
percent recovery was performed. Percentage recovery 
was within the range of 99.41 to 100.79 for 
Hydrochlorothiazide, 99.34 to 100.82 for 
Dihydralazine and 99.77 to 100.93 for Propranolol 
which specifies the accuracy of the method. 
Precision  
For the precision study, repeatability study was carried 
out for brief time interval under the same 
chromatographic condition. The sample was injected in 
six replicates. The peak area for all the six replicates 
was recorded. The mean and % relative standard 
deviation (%RSD) was calculated and the results are 
shown in table 6. The %RSD for Hydrochlorothiazide, 
Dihydralazine, and Propranolol were found to be 
0.64%, 0.94%,and0.87 % respectively. From the 
obtained data the established RP-HPLC method was 
found to be accurate. For interday and intraday 
precision three different concentrations (50%, 100% 
and 150% of analyte) of standard solutions were 
injected on thesame day and three consecutive days in 
three replicates and results were recorded in table 7 & 
8. 
Limit of Detection (LOD) and Limit of 
Quantification (LOQ) 
The standard deviation of response and calibration 
curve slope were used for calculation of limit of 
detection and quantification and results are recorded 
table 9. The LOD for Hydrochlorothiazide, 
Dihydralazine, and Propranolol was found to be 
0.842μg/ml, 1.956μg/ml,and1.282μg/ml respectively. 
The LOQ is the lowestanalyteconcentration, which 
gives areply that can be preciselymeasured. The LOQ 
for Hydrochlorothiazide, Dihydralazine,and 
Propranolol was 2.551μg/ml, 
5.927μg/ml,and3.886μg/ml. 
Robustness 
Robustness of the method was evaluated by making 
minorcautious variations in chromatographic 
conditions such asmobile phase ratio, flow rate, as well 
as buffer pH and the result was recorded in table 10.It 
was detected that there were no noticeable deviations 
in chromatograms and % relative standard deviation 
was found below 2%, which confirmed that the 
established RP-HPLC method is robust. 
Specificity 
The specificity of the proposed method is justified by 
the chromatograms of blank, placebo, standard and 
sample solutions under same chromatographic 
conditions shown in figure 9. The placebos did not 
interfere in the determination of Hydrochlorothiazide, 
Dihydralazine, and Propranolol in acommercial tablet. 
Specificity of the established method was also checked 
by diverse types of stress conditions (base, acid, 
oxidation, thermal and photolytic) to 
Hydrochlorothiazide, Dihydralazine, and Propranolol 
tablet. 
Degradation Study 
From the results of forced degradation studies showed 
that these components do not remain intact under 
stressed conditions and hence special storage 
conditions should be provided for the dosage form. The 
specificity studies showed that the principle peaks were 
well resolved (peak purity 99.99%) and free from any 
interference from the degradation product. The stress 
conditions were applied and degraded products of all 
three drugs are compared and showed in table 11 and 
chromatograms are in figure 10. It is concluded from 
the stress studies that substantial degradation of 
Hydrochlorothiazide, Dihydralazine, and Propranolol 
occurred in acid, basic, oxidative thermal and 
photolytic stress conditions. The degradation products 
(impurities) in addition to percent degradation under 
base, acid, thermal, oxidation, and photolytic stresses 
have unique retention times (RT) to acidic stress (9 
impurities, RT: 2.563 min, 2.677 min, 3.310 min, 4.707 
min, 5.720 min, 7.377 min, 7.813 min, 9.160 min and 
11.263 min), basic stress (9 impurities, RT: 2.500 min, 
2.637 min, 3.247 min, 4.627 min, 5.817 min, 6.850 
min, 9.037 min, 10.233 min and 12.057 min), oxidative 
stress (10 impurities, RT: 2.457 min, 2.580 min, 3.180 
min, 4.493 min, 5.973 min, 6.920 min, 7.283 min, 
8.870 min, 10.573 min and 12.250 min), thermal stress 
(11 impurities, RT: 2.500 min, 2.633 min, 3.247 min, 
4.630 min, 5.220 min, 5.817 min, 6.690 min, 7.787 
min, 9.027 min, 10.867 min and 11.690 min) and 
photolytic stress (8 impurities, RT: 2.490 min, 2.633 
min, 3.247 min, 4.267 min, 5.817 min, 7.007 min, 
8.053 min and 9.027 min). Degradation studies 
justified the method specificity for its intended 
application. 
 
Results and Discussion 
For developing a novel RP-HPLC method, numerous 
compositions of mobile phase were tried.Anacceptable 
separation and good peak proportion was attained with 
BDS hypersil C18, 250mm×4.6mm internal diameter, 
5µ particle size or equivalent column and mobile phase 
comprising of Buffer (0.05 M potassium dihydrogen 
orthophosphate) pH 6.0 : Acetonitrile (40:60v/v) at a 
1.0 ml/min flow rate to get improved reproducibility in 
addition to repeatability. Quantification was 
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accomplished with UV detection at 215nm based on 
peak area. The retention time for Hydrochlorothiazide, 
Dihydralazine and Propranolol were found to be 3.227 
min, 9.097 min,and 5.807 min respectively. 
According to the ICH guidelines optimized method 
was authenticated. The parameters of system suitability 
were detected by using this optimized condition were 
testified. The method was found to be linear in the 
concentration range of 10-30 𝜇g/mL with correlation 
coefficient of 0.9996 for Hydrochlorothiazide, 12.5-
37.5 𝜇g/mL with correlation coefficient of 0.9986 for 
Dihydralazine, and 20-60 𝜇g/mL with correlation 
coefficient of 0.9997 for Propranolol. The results of 
recovery study (99.42% for Hydrochlorothiazide, 
99.34% for Dihydralazine and 99.77% for Propranolol) 
suggest that the method has good recovery. The 
accuracy of the projected method was carried in terms 
of the repeatability. The low% RSD (<2) values of 
0.58%, 0.44% and 0.87% variation for 
Hydrochlorothiazide, Dihydralazine and Propranolol, 
respectively, reveals that the proposed method is 
precise. The LOD and LOQ values for 
Hydrochlorothiazide were found to be 0.842μg/ml and 
2.551μg/ml, for Dihydralazinewere 1.956μg/ml and 
5.927μg/ml and for Propranolol were 1.282μg/ml and 
3.886μg/ml. The outcomes of robustness in the current 
method exhibited no significant variations. The 
outcomes of drop analysis specified that no 
interference due to common excipients was detected 
with the developed method. Degradation studies 
justified the method specificity for its intended 
application. Consequently, the projected method can be 
used for routine analysis of three drugs as a 
combination in pharmaceutical dosage form. 
 
 
FIGURE 1: Structure of Hydrochlorothiazide 
 
FIGURE 2: Structure of Dihydralazine 
 
FIGURE 3: Structure of Propranolol 
 
Asian Pac. J. Health Sci., 2017; 4(3):292-305                                          e-ISSN: 2349-0659,   p-ISSN: 2350-0964                         
____________________________________________________________________________________________________________________________________________  
 ____________________________________________________________________________________________________________________________________________  
Sharma et al                               ASIAN PACIFIC JOURNAL OF HEALTH SCIENCES, 2017; 4(3):292-305 
www.apjhs.com                                    297 
 
 
 
FIGURE 4: Overlay absorption spectrum for Hydrochlorothiazide, Dihydralazine and Propranolol 
 
FIGURE 5: Standard Chromatograms of Hydrochlorothiazide, Dihydralazine and Propranolol. 
 
FIGURE 6: Calibration curve of Hydrochlorothiazide 
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FIGURE 7: Calibration curve of Dihydralazine 
 
FIGURE 8: Calibration curve of Propranolol 
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(b) 
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(f) 
 
FIGURE 9: Chromatograms of (a) Blank, (b) Hydrochlorothiazide, (c) Dihydralazine,(d) Propranolol, (e) 
Standard mixture and (f) Sample mixture. 
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FIGURE10: Chromatograms of (a) Acid Degradation, (b) Base Degradation (c) Oxidative Degradation, (d) 
Thermal Degradation, (e) Photolytic Degradation 
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TABLE 1: System suitability of proposed method 
Parameters Hydrochlorothiazide Propranolol Dihydralazine 
Theoretical plates 5768 7297 5989 
Resolution - 11.678 8.867 
Asymmetry 1.478 1.368 1.524 
Retention time 3.227 min 5.807 min 9.097 min 
 
 
TABLE 2: Linearity results of Hydrochlorothiazide 
 
Linearity Level Concentration Area 
I 10 µg/ml 495.645 
II 15 µg/ml 742.735 
III 20 µg/ml 977.866 
IV 25 µg/ml 1220.885 
V 30 µg/ml 1430.128 
Correlation coefficient 0.9996 
TABLE 3: Linearity of Dihydralazine 
 
Linearity Level Concentration Area 
I 12.5µg/ml 3255.054 
II 18.75 µg/ml 4860.674 
III 25 µg/ml 6375.283 
IV 31.25 µg/ml 7975.126 
V 37.5 µg/ml 9153.15 
Correlation coefficient 0.9986 
 
TABLE 4: Linearity of Propranolol 
Linearity Level Concentration Area 
I 20 µg/ml 2031.625 
II 30 µg/ml 3059.895 
III 40 µg/ml 3953.914 
IV 50 µg/ml 5002.322 
V 60 µg/ml 5950.533 
Correlation coefficient 0.9997 
 
TABLE 5: Results of Accuracy 
Sample Accuracy Standard Drug 
(µg/ml) 
Sample Drug 
(µg/ml) 
% of 
recovery 
S.D. % 
RSD 
Hydrochlorothiazide 80% 8 10 100.79 0.372 0.369 
100% 10 10 99.42 0.581 0.585 
120% 12 10 99.92 0.964 0.965 
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Dihydralazine 80% 20 20 100.82 0.956 0.948 
100% 25 20 99.34 0.437 0.439 
120% 30 20 99.59 0.533 0.536 
Propranolol 80% 16 20 100.93 0.706 0.699 
100% 20 20 99.77 0.872 0.874 
120% 24 20 100.36 0.979 0.976 
 
TABLE 6: Results of Precision 
 
Injection Area of Hydrochlorothiazide Area of Dihydralazine Area of Propranolol 
Injection 1 2315.318 6343.359 3960.402 
Injection 2 2336.179 6346.676 3996.157 
Injection 3 2329.078 6381.17 3955.152 
Injection 4 2338.505 6432.34 4016.157 
Injection 5 2317.699 6350.251 3928.912 
Injection 6 2299.173 6250.539 3933.387 
Average 2322.659 6350.723 3965.028 
S.D. 14.87 59.49 34.66 
% RSD 0.64 0.94 0.87 
 
TABLE 7: Result of Interday Precision 
Conc. (µg/ml) Area % RSD 
Hydrochlo
rothiazide 
Dihydr
alazine 
Propra
nolol 
Hydrochlor
othiazide 
Dihydralaz
ine 
Propranolo
l 
Hydrochlo
rothiazide 
Dihydr
alazine 
Propra
nolol 
10 12.5 20 1154.135 3157.043 1971.538 1.11 1.35 1.12 
20 25 40 2287.448 6270.128 3926.208 1.19 1.32 0.89 
30 37.5 60 3495.995 9557.916 5946.82 0.87 1.18 1.39 
TABLE 8: Result of Intraday Precision 
 
 
Conc. (µg/ml) Area % RSD 
Hydrochlo
rothiazide 
Dihydr
alazine 
Propra
nolol 
Hydrochlor
othiazide 
Dihydralaz
ine 
Propranolo
l 
Hydrochlo
rothiazide 
Dihydr
alazine 
Propra
nolol 
10 12.5 20 1156.495 3149.166 1972.940 0.46 1.07 0.86 
20 25 40 2307.016 6303.459 3948.564 0.51 0.64 0.53 
30 37.5 60 3481.917 9549.102 5936.898 0.32 0.42 0.66 
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TABLE 9: Results of LOD and LOQ 
 
Parameter Hydrochlorothiazide 
(µg/ml) 
Dihydralazine(µg/ml) Propranolol (µg/ml) 
LOD 0.842 1.956 1.282 
LOQ 2.551 5.927 3.886 
 
TABLE 10: Results of Robustness 
 
Conditi
on 
Variatio
n 
Average Area % RSD 
Hydrochlorothi
azide 
Dihydralaz
ine 
Propranol
ol 
Hydrochlorot
hiazide 
Dihydralaz
ine 
Proprano
lol 
Flow 
rate 
0.8 min 2515.472 6839.027 4290.518 0.46 0.58 0.72 
1.2 min 2179.172 5952.714 3717.522 0.45 0.48 0.91 
Mobile 
phase 
Buffer: 
Acetonitr
ile 
42:58 
2270.496 6212.749 3874.363 0.41 0.59 0.62 
Buffer: 
Acetonitr
ile 
38:62 
2411.253 6577.917 4147.491 0.54 1.57 0.18 
pH 6.2 2260.816 6168.885 3854.81 0.29 0.89 0.27 
5.8 2387.002 6490.618 4071.495 0.64 0.98 1.12 
 
TABLE 11: Stability study results 
 
Type of 
degrada
tion 
Drug Peak Area 
of Standard 
Conditions Peak area 
Standard Sample 
Area % Deg. Area % 
Deg. 
Acid 
degra
dation  
Hydrochlorothiazi
de 
2343.368 4 hours at 
Room 
Temperature 
1558.557 33.49 1591.252 32.10 
Dihydralazine 6420.129 4575.326 28.73 4504.732 29.83 
Propranolol 4008.286 3254.047 18.82 3130.804 21.89 
Base 
degra
dation  
Hydrochlorothiazi
de 
2343.368 3.5 hours at 
Room 
Temperature 
1657.651 29.26 1688.807 27.93 
Dihydralazine 6420.129 4431.61 30.97 4583.77 28.60 
Propranolol 4008.286 2970.3 25.90 2947.021 26.48 
Oxidat Hydrochlorothiazi 2343.368 4 hours at 1472.438 37.17 1341.413 42.76 
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ive 
degra
dation  
de Room 
Temperature 
Dihydralazine 6420.129 4151.979 35.33 4068.656 36.63 
Propranolol 4008.286 2737.088 31.71 2664.427 33.53 
Therm
al 
degra
dation  
Hydrochlorothiazi
de 
2343.368 3 hours at 
1050C 
1612.177 31.20 1623.205 30.73 
Dihydralazine 6420.129 4629.325 27.89 4562.647 28.93 
Propranolol 4008.286 3202.095 20.11 3229.27 19.43 
Photol
ytic 
degra
dation  
Hydrochlorothiazi
de 
2343.368 3 hours in 
direct Sun 
light 
1637.398 30.13 1619.625 30.88 
Dihydralazine 6420.129 4595.188 28.42 4630.243 27.88 
Propranolol 4008.286 3171.32 20.88 3212.114 19.86 
 
Conclusion 
A simple, precise, accurate and rapid method was 
established for instantaneous valuation of 
Hydrochlorothiazide, Dihydralazine, and Propranolol 
from pure and its dosage forms. The mobile phase is 
easy to prepare and cost-effective. The recoveries of 
the sample in the preparation were in good 
arrangement with their particular label claims. 
Henceforth, this method can be effortlessly and 
suitably accepted for routine analysis of 
Hydrochlorothiazide, Dihydralazine, and Propranolol 
in pure form and its dosage form. 
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